EUCTR2011-006132-24-GB进行中（未招募）1 期
A multi-centre 3-year follow-up study to assess the viral activity in patients who failed to achieve sustained virologic response in Novartis-sponsored alisporivir studies for chronic hepatitis C patients
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 105
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Written informed consent must be obtained before any assessment is performed
- •-Males or females aged 18 or greater
- •-Have previously completed a Novartis-sponsored hepatitis C study and received alisporivir or a direct antiviral agent
- •-Have not acheived SVR24
- •-Are able to comply with visit schedule
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 650
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-Use of any investigational drugs within 5 half-lives of enrollment, or within 30 days of that medication, whichever is longer
- •-Previous use of any course of hepatitis C therapy since the end of the Novartis-sponsored hepatitis C study
研究者
相似试验
进行中（未招募）
不适用
A 3-year follow-up study in chronic hepatitis C patients who failed to achieve sustained virologic response during Novartis-sponsored alisporivir studiesEUCTR2011-006132-24-HUovartis Pharma Services AG650
进行中（未招募）
不适用
A 3-year follow-up study of chronic hepatitis C patients treated with alisporivir to assess durability of sustained virologic responseEUCTR2011-006131-38-GBovartis Pharma Services AG2,000
进行中（未招募）
3 期
A study to assess thedurability of sustained virologic response in Alisporivirtreatedchronic Hepatitis C patientsCTRI/2012/10/003066ovartis Healthcare Pvt Lt2,000
进行中（未招募）
不适用
A 3-year follow-up study in chronic hepatitis C patients who failed to achieve sustained virologic response during Novartis-sponsored alisporivir studiesChronic hepatitis C patients who failed to achieve sustained virologic response (SVR24) on alisporivir or direct-acting antivirals (DAA) in previous Novartis-sponsored studies.MedDRA version: 14.1Level: SOCClassification code 10021881Term: Infections and infestationsSystem Organ Class: 10021881 - Infections and infestationsEUCTR2011-006132-24-ESovartis Farmaceutica, S.A.650
进行中（未招募）
不适用
A 3-year follow-up study of chronic hepatitis C patients treated with alisporivir to assess durability of sustained virologic responseEUCTR2011-006131-38-ITOVARTIS FARMA2,000